Finally, through the TGF-β1/Smads and PI3K/Akt pathway, QUE exerts antifibrotic effects that are critical for slowing or preventing fibrosis progression in MASLD. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatotic liver disease.